SMEDDS: Emerging Technique For Enhancement Of Drug Solubility And Bioavailability

Mohammad Junaid Alam Mansoori[1], Dr. Amul mishra[2]

[1]*Research Scholar, Faculty of Pharmacy, Bhupal Nobles' University, Udaipur-313001, Rajasthan
[2]Associate Professor, Bhupal Nobles' University, Udaipur-313001, Rajasthan

***Corresponding Author: -** Mohammad Junaid Alam Mansoori
*Research Scholar, Faculty of Pharmacy, Bhupal Nobles' University, Udaipur-313001, Rajasthan

ABSTRACT
Oral drug administration is favored for its inherent convenience and minimal discomfort. However, the oral bioavailability of newly developed pharmaceutical compounds often faces challenges due to their poor dissolution rates. To address this issue, innovative strategies have been devised to enhance drug absorption. The aforementioned strategies encompass many methodologies, namely consolidation, cocrystals, solid dispersions, and pH level management, including lipid-based methods for delivery. Among these techniques, self-microemulsifying formulations (SMEDDS) have garnered significant attention as highly efficient lipid-based delivery systems.
SMEDDS exhibit remarkable properties with droplet sizes as small as 100 nanometers. They not only facilitate drug permeation across the intestinal membrane but also protect it from degradation in the stomach. Additionally, SMEDDS simplify dosing regimens, elevate overall drug bioavailability, and reduce the required dosage. These formulations are formulated from a diverse array of components that collectively enhance oral bioavailability by The concept of bypassing hepatic first-pass metabolism pertains to the process of drug metabolism in which the drug concentration undergoes substantial reduction prior to entering the systemic circulation, primarily as a result of hepatic metabolism.
The present critical review aims to provide an extensive examination of the formulation development, underlying mechanisms, in addition classification of SMEDDS. It serves as an essential resource for understanding the pivotal role played by SMEDDS in improving oral drug delivery, offering insights into their multifaceted potential and application in pharmaceutical research and development.

Keywords: SMEDDS, Composition, Biopharmaceutical, Formulation, Oral Bioavailability, Novel medication distribution systems.

Introduction

The dispensation of medicinal compounds via oral pharmaceutical conveyance is a greatly favored technique owing to its innate convenience. Nonetheless, this occurrence poses myriad substantial hurdles that affect more than 40% of freshly devised therapy opportunities. The primary apprehensions involve insufficient bioavailability, substantial variances in the reaction to medication among individuals, and a scarcity of proportionality in dosing. To address these challenges, academics have employed numerous strategies in formulating their research methodologies.

One approach involves the amalgamation of assorted elements, encompassing agents like surfactants and fats, enhancers for permeability, diminishment in particle size, formation of salts, cyclodextrins, nanoparticles, and compact distributions. The fundamental goal of these tactics is to enhance the solubility and assimilation of therapeutic agents within the gastrointestinal system. Lipid-grounded configurations have garnered notable attention in the sphere, notably because of the remarkable potential of self-emulsifying pharmaceutical transportation methods in heightening the oral assimilation of fat-soluble remedies. [1].

The phrase "self-spreading oily compositions" alludes to consistent blends consisting of organic or artificial oils, compact or liquid surface-active agents, and multiple water-attracting solvents and auxiliary agents/surface-active agents. These arrangements have the capability to autonomously create tiny emulsions or oil-in-water (o/w) emulsions with gentle disturbance, which are subsequently capable of being thinned out in watery solutions, such as fluids within the gastrointestinal (GIT) tract. These preparations are alternatively known as self-propelled microemulsion pharmaceutical transport systems or SMEDDS. The introduction of small oil droplets aims to expedite the transit of medicinal compounds through the stomach, reducing their interaction with the gastrointestinal (GI) wall and enhancing drug dispersion throughout the GI tract. Unlike conventional emulsions, which may be fragile and unstable, SMEDDS offer physical stability and ease of production, requiring fewer processing demands. Their primary advantage over traditional oily solutions is the expanded interfacial area, facilitating drug partitioning between the oil and water phases [2].

Numerous formulation methods have been created to confront the difficulties presented by inadequately water-dissolvable drugs. These methods include micronization, solid dispersion, and cyclodextrin complexation. While they have demonstrated efficacy in specific cases, they are not without limitations. Micronization, for instance, may compromise the chemical and thermal stability of pharmaceutical substances and their bioactivity. Solid dispersion creation often requires substantial amounts of carriers, leading to large tablets or capsules, particularly when higher dosages of the active component are necessary. This process can also incur significant costs due to the use of expensive carriers and specialized equipment, including techniques like freeze-drying or spray-drying [3]. The conventional solvent approach can serve as an alternative, but the use of high-viscosity coprecipitates presents considerable challenges. Furthermore, substances that are not soluble in either watery or organic solvents cannot be efficiently combined with cyclodextrins. Acknowledging the possibility of enhancing the oral bioavailability of medicines with limited water dissolvability when given alongside a rich fatty meal, noteworthy focus has shifted to investigating the potentials of SMEDDS. [4].

Diverse fat-centered pharmaceutical transportation techniques involve fat resolutions, fat suspensions, tiny suspensions, and dehydrated suspensions. To gain an improved comprehension and sorting of the wide array of compositions and adjunct amalgamations within self-scattering setups, the lipid formula classification scheme has been introduced. The classification system serves as a valuable tool for comprehending how different lipid formulations behave within living organisms, facilitating a systematic and rational approach to formulation development. It reduces the need for repetitive trial-and-error experiments and establishes a foundation for regulatory communication. The lipid formulation classification system was originally developed by Pouton in 2000, with a recent update documented [5]. Table 1 exhibits the categorization of fat-focused preparations through the lipid formula classification structure, taking into account their makeup and the possible consequences of dilution and assimilation on the formulation's capability to avert medication precipitation.

In summary, oral drug delivery faces challenges related to low bioavailability, inter-individual variability, and dose proportionality. Researchers have developed various strategies, with lipid-based formulations, particularly SMEDDS, offering promising solutions to improve the oral bioavailability of lipophilic drugs. The LFCS provides a valuable framework for categorizing and understanding the behavior of different lipid formulations, enhancing the development of effective drug delivery systems.

Table 1. Compositions and characteristics of lipid-based formulation.

Composition	**Type I**	**Type II**	**Type III**		**Type IV**
	Oil (%)	**SEDDS (%)**	**IIIA SEDDS (%)**	**IIIB SMEDDS (%)**	**Oil-Free (%)**
Glycerides	100	40-80	40-80	<20	-
Surfactants (HLB < 12)	-	20-60	-	-	0-20
Surfactants (HLB > 12)	-	-	20-40	20-50	20-80
Hydrophilic co-solvents	-	-	0-40	20-50	0-80
Particle size of dispersion (nm)	Coarse	100-250	100-250	50-100	<50
Significance of aqueous dilution	Minor significance	The capacity of the solvent is unaltered.	A modest decline in solvent capacity		Prominent phase transitions and possible solvent capacity depletion
Significance of digestibility	Important necessitates	This phenomenon is not of utmost importance, however, it is highly probable to transpire.	Non-essential but potentially impeded		Unrequired and improbable to transpire
Materials	Oils that don't contain any sort of solvent (such tri-, di-, or monoglycerides)	The topic of interest is surfactants that are	Co-solvents (encompassing water-dissolvable and water-unstirred adjuncts), greases, and emulsifying agents.		Substances and agents that dissolve in water (lacking any oils).

		insoluble in water and oils.		
Characteristics	Dispersal is not possible; must be digested	SEDDS can be produced without water-dissolvable constituents.	SEDDS/SMEDDS that are composed of water-soluble constituents	Typically, the formulation disperses into a micellar solution.
Advantages	Safe for human consumption; easy to use; top-notch capsule Compatibility	It is improbable for the dispersion to see a reduction in solvent capacity.	An almost transparent dispersion of the medication Non-digestive absorption	Formulation has an excellent capability to dissolve numerous drugs.
Disadvantages	Unless the medicine is very lipophilic, the formulation has a low capacity to dissolve it.	The dispersion of oil-in-water emulsion, is characterised by turbidity and contains particles with a size range of 0.25 to 2 μm.	There is a potential risk of solvent capacity reduction in the dispersion. more difficult to comprehend	Probably attenuated solvent capacity during dispersion; potentially indigestible.

The Pharmaceutical Bio-Classification System is a crucial framework in the realm of pharmaceutical studies, formulated to classify medications according to their characteristics related to solubility and permeability. It serves as a fundamental instrument for projecting the probability of in vitro-in vivo correlations for prompt-release dosage formats. It is firmly grounded in the recognition that two primary factors—medication solubility/dissolution attributes and gastrointestinal permeability—play a central part in determining the speed and extent of drug assimilation [11]. The ensuing discussion explores the diverse groupings within BCS, with specific focus on fat-focused pharmaceutical transport schemes.

Type I systems represent drug formulations predominantly involving solubilization within triglycerides, blended glycerides, or encapsulation within oil-in-water emulsions. To maintain stability, these emulsions rely on small quantities of emulsifiers, typically including polysorbate 60 at 1% w/v and lecithin at 1.2%. However, due to their initial limited dispersion in aqueous environments, Type I systems require digestion in the gastrointestinal tract (GIT), a process facilitated by pancreatic lipase and co-lipase. This digestive step is crucial as it primes to the creation of lipid ingestion products through improved amphiphilic properties, which, in turn, assist in the transport of drugs into the colloidal aqueous phase [6].

Within the realm of Type I lipid formulations, they are particularly suitable for drugs possessing potent characteristics or compounds with a high affinity for lipids, ensuring adequate solubility in oils to accommodate the required drug payload [7].

Type II systems, on the other hand, encompass SEDDS and fall into the category of Type II lipid-based formulations. In such systems, surfactant concentrations exceeding 25% (w/w) are often sufficient to achieve self-emulsification. Nevertheless, it's vital to acknowledge that the emulsifying procedure might confront obstacles when elevated amounts of surface-active agents are in the mix. These impediments surface as the establishment of dense liquid crystalline gels at the interface between the oil and water, particularly when surfactant levels surpass 50-60% (w/w), depending on the specific components involved. As previously mentioned, Type II Fat-focused compositions provide significant interfacial surfaces, encouraging the effective dispersion of therapeutic substances between fat globules and the watery stage, where assimilation transpires[8].

Classification III introduces self-propelling microemulsion drug transport systems (SMEDDS), a category of fat-centered arrangements characterized by the inclusion of water-attracting surface-active agents with a hydrophilic-lipophilic balance (HLB) value surpassing 12. These compositions also incorporate auxiliary agents such as ethanol, propylene glycol, and polyethylene glycol. To distinguish Type III compositions from Type IIIB compositions, which are more water-attracting due to an increased quantity of water-attracting surface-active agents and auxiliary agents, Type III can be additionally divided into Type IIIA and Type IIIB compositions, though this distinction is somewhat subjective. Type IIIB compositions entail a greater risk of drug precipitation during the dispersal process compared to Type IIIA, chiefly because of their reduced fat content. Nevertheless, Type IIIB compositions usually exhibit superior dispersion rates in contrast to Type IIIA compositions [9].

Within the framework of Category IV compositions, this subgroup appeared as a reaction to the increasing favor of compositions chiefly relying on water-attracting surface-active agents and auxiliary agents. Category-IV compositions are recognized by a substantial level of water-attracting qualities because of the lack of spontaneously present fat substances. These compositions frequently result in elevated drug loads in comparison to compositions utilizing fundamental glyceride

fats. They also generate extremely pure scatterings when introduced into watery settings. Nevertheless, uncertainties surface concerning the comparative capacity for dissolving substances within these systems, there in vivo performance in formulations containing natural oils, and their ability to effectively maintain weakly water-soluble medications in solution during gastrointestinal transit, akin to Type-II and Type-III formulations. Notably, the amprenavir capsule formulation, an HIV protease inhibitor, represents a Type-IV formulation due to the incorporation of TPGS as a surfactant, in conjunction with co-solvents like PEG 400 and propylene glycol [10].

To conclude, the Pharmaceutical Bio-Classification System is a precious instrument for classifying pharmaceuticals contingent on their attributes related to solubility and permeability. In this structure, different fat-focused pharmaceutical transportation systems, including Type I, Type II, Type III, and Type IV compositions, offer custom-made methodologies to boost pharmaceutical solubility, reliability, and eventually, bioavailability. Every classification within BCS possesses its distinct traits, applications, and deliberations, permitting pharmaceutical researchers to establish well-informed selections in the construction of efficient pharmaceutical transportation systems.

Table 2. BCS classification.

Class	**Description**
Class-I	Profound soluble Extremely permeable
Class-II	minimal solubility Extremely permeable
Class-III	Profound soluble minimal permeability
Class-IV	minimal solubility minimal permeability

BCS, as regulated by the Food and Drug Administration, lays down specific criteria pertaining to the solubility and permeability classes within this framework. Solubility is fundamentally distinct as the capability of a substance to dissolve in a specified bulk of aqueous solution under specific conditions. In the context of BCS, "high solubility" is established when a medicinal substance can dissolve in 250 milliliters or a lesser amount of of an aqueous solution with a pH range from 1 to 7.4. This solubility is considered at equilibrium and at a temperature of 37°C [12].

On the flip side, permeability indicates a material's ability to allow the passage of substances. To achieve the classification of "highly permeable" within the BCS framework, a drug compound must exhibit a minimum absorption rate of 90% of the given dose in humans. This determination can be confirmed either through mass balance calculation or by comparing it to an intravenous reference dose. Additionally, it is crucial that there are no signs of the drug's instability in the gastrointestinal tract, a state that can be verified through absolute bioavailability investigations [13].

Shifting our focus to self-propelling microemulsion pharmaceutical conveyance systems (SMEDDS), these formulations present a noteworthy characteristic. When gently stirred and subsequently diluted in watery solutions, such as gastrointestinal fluids, SMEDDS reveal an exceptional capacity to produce finely dispersed oil-in-water (o/w) microemulsions. The components used in SMEDDS preparations encompass a range of natural or artificial oils, both compact and liquid surface-active agents, as well as one or more water-attracting solvents and auxiliary agents/surface-active agents. The self-emulsifying process takes place naturally within the gastrointestinal (GI) tract, driven by the mechanical mixing resulting from the digestive movements of the stomach and intestines. In comparison, self-propelling pharmaceutical transportation systems (SEDDS), also known as self-spreading oily compositions (SEOF), generally generate cloudy emulsions characterized by droplet sizes spanning from 100 to 300 nanometers [14].

On the contrary, self-spreading pharmaceutical transport systems (SMEDDS) present the unique characteristic of creating see-through microemulsions, where drop dimensions dip beneath 100 nanometers, and the oil concentration remains below 20%. In contradistinction to conventional emulsions, which are fragile and relatively unstable dispersion structures, SMEDDS are celebrated for their physical steadiness and simplicity of production. This indicates that the adoption of these systems bears the potential to boost the speed and scale of assimilation, resulting in more even blood-time patterns, especially for lipophilic drug compounds confronting limitations in absorption due to their dissolution rate. The preliminary step in applying SMEDDS requires identifying an oil-surfactant mix that can effectively break down the drug to accomplish the necessary therapeutic level. This SMEDDS blend can be enclosed in either soft or firm gelatin capsules. Usual elements located in self-spreading pharmaceutical conveyance systems encompass a variety of ingredients such as fats, surface-active agents, and antioxidants, often complemented with co-surface-active agents and co-solvents to amplify their attributes [15].

The acceptance of Self-Spreading Pharmaceutical Transport Systems (SMEDDS) offers a plethora of advantages. One of the notable perks is the substantial improvement in oral bioavailability. This enhancement stems from the expanded particular surface region facilitated by SMEDDS, allowing for more efficient drug transfer between the watery boundary layer in the intestines and the absorptive membrane. This, in turn, leads to an overall improvement in bioavailability. To exemplify, research has indicated that the bioavailability of halofantrine is significantly greater, roughly 6-8 times, when given in liquid form in contrast to tablet form [16]. Figure 1 delivers an all-encompassing summary of the range of benefits correlated with microemulsion compositions.

In essence, the incorporation of SMEDDS represents a promising and innovative strategy for addressing challenges related to drug bioavailability, particularly for compounds characterized by limited solubility and dissolution rate. This approach

has the potential to revolutionize drug delivery and significantly improve therapeutic outcomes, making it a subject of significant interest and importance in the field of pharmaceutical research and development.



Figure 1. Various advantages of microemulsion formulations.

In the pharmaceutical industry, the seamless manufacturing and scalability of drug delivery technologies are paramount considerations, particularly when seeking to enhance bioavailability. Among these technologies, Self-Microemulsifying Drug Delivery Systems offer notable advantages in terms of simplicity in production and scalability, distinguishing them from alternatives like solid dispersions, liposomes, and nanoparticles. The key to efficient SMEDDS manufacturing lies in the design of production facilities characterized by simplicity and cost-effectiveness. Equipping these facilities with essential tools, like basic mixers with agitators and volumetric fluid loading apparatus, enables cost-effective mass production. This cost-efficiency and production simplicity have made SMEDDS an appealing choice for pharmaceutical companies aiming to improve the bioavailability of their drug products, garnering significant interest within the commercial sector [17].

The central aim of the current research revolves around the examination of elements affecting between-subject and within-subject differences and how nutritional elements influence medication effectiveness. Fluctuations in the assimilation of drugs, both amidst people and within the identical person at diverse intervals, can profoundly influence the efficiency of treatment and the adherence of the patient. Nutritional consumption performs a crucial function in the therapeutic efficiency of a drug. Within this context, SMEDDS has emerged as a favorable option within the pharmaceutical landscape. Multiple published studies have consistently demonstrated that Self-Microemulsifying Drug Delivery Systems (SMEDDS) remain unaffected by dietary factors. These studies have consistently shown that SMEDDS yield reproducible plasma profiles, effectively mitigating the influence of absorption variability and ultimately enhancing treatment outcomes [18].

SEDDS display two evident qualities that differentiate them from established drug conveyance methods. Initially, they have the competence to convey substantial molecules, covering peptides, hormones, enzyme compounds, and suppressors. Second, they provide a safeguard against enzymatic decomposition in the gastrointestinal system., a crucial feature when dealing with bioactive molecules susceptible to enzymatic degradation. Emulsifying agents like polysorbate 20 in microemulsion formulations serve as protective barriers, preventing the hydrolysis of prodrugs by gastrointestinal enzymes like cholinesterase. Moreover, SMEDDS are well-suited for storing thermolabile medicines, including peptides, due to their spontaneous formation without the need for energy or heating. This mechanism positions SMEDDS as a valuable platform for the delivery and preservation of fragile biopharmaceuticals, ensuring their efficient absorption and therapeutic efficacy [19]. Figure 2 provides a visual representation of the process of SMEDDS uptake.

In conclusion, SMEDDS' advantages in terms of manufacturing simplicity, scalability, and their ability to reduce absorption variability, along with their capacity to transport and shield sensitive macromolecules, establish them as a versatile and compelling option in the realm of drug delivery. This has significant implications for enhancing the effectiveness of pharmaceutical products.



Figure 2. Schematic representation of uptake of SEDDS with different pathways.

Exploring the Impact of Fat Digestion on SMEDDS

SMEDDS have emerged as a potent tool for overcoming the solubility challenges of poorly water-soluble medicines, elevating the prospects of effective medication delivery to the systemic circulation. Their unique resistance to the fat digestion process is a distinctive attribute that sets them apart from other drug delivery technologies. This comprehensive analysis delves into the ramifications of this resistance, the resulting augmentation in drug loading capacity, and the comparative advantages over conventional emulsion-based drug delivery systems.

Resistance to Fat Digestion

The unparalleled performance of SMEDDS is underpinned by their remarkable resilience against critical processes like lipolysis, emulsification facilitated by bile salts, the enzymatic activities of pancreatic lipases, and the formation of mixed micelles. These processes wield significant influence over the effectiveness of lipid-based drug delivery systems. In stark contrast, SMEDDS operate autonomously, bypassing the need for pre-absorptive digestion in certain scenarios [20].

This resistance to fat digestion is a compelling advantage for drugs characterized by low solubility in water. Typically, these drugs necessitate enzymatic digestion for absorption. By circumventing dependence on digestive processes, SMEDDS offer a more efficient and reliable means of drug delivery. It is essential to recognize that this resistance fosters predictability and consistency in drug delivery, mitigating the variability stemming from disparities in individual fat digestion efficiencies.

Enhanced Drug Loading Capacity

The solubility of drugs, particularly those characterized by moderate partition coefficients (log P > 4) and poor water solubility, often serves as the ultimate limitation in oral bioavailability. The conventional lipid-based delivery systems, using natural lipids, frequently fall short in providing the requisite solubility for such drugs. However, SMEDDS formulations, rich in amphiphilic surfactants, co-surfactants, and co-solvents, transcend these limitations by substantially augmenting drug solubility. This increased solubility capacity translates into a substantially augmented drug loading capacity in SMEDDS, surpassing that of conventional lipid solutions [21].

The boost in drug loading capacity in SMEDDS is transformational for drug formulation. It permits the incorporation of higher drug dosages within a single dosage form, potentially reducing the frequency of patient dosing. This advancement not only enhances patient adherence to treatment but also grants greater flexibility in drug dosing, a hallmark of personalized medicine. By offering a versatile platform for delivering a spectrum of drugs, SMEDDS emerges as a pivotal tool for optimizing drug therapies, ensuring precision in dosing and maximizing the therapeutic benefits for patients.

Advantages Over Conventional Emulsion-Based Systems

Traditional emulsion-based drug delivery systems have been instrumental in augmenting the solubility of hydrophobic drugs. Nevertheless, they grapple with certain limitations, particularly the phenomenon of creaming, which often surfaces during extended storage periods. Creaming occurs when an emulsion segregates into distinct layers, jeopardizing the uniformity and stability of the drug product. SMEDDS, as an integral facet of thermodynamically stable systems, remains

impervious to the creaming phenomenon. This robust stability enables the convenient, long-term storage of SMEDDS without concerns about the physical integrity of the formulation. Furthermore, the microemulsions generated by SMEDDS are distinct from traditional emulsions in two key aspects.

Foremost, it's the size of the droplets within the microemulsions. While traditional emulsions host droplets spanning from 2 to 10μm, SMEDDS consistently crafts droplets in the nanometer range, approximately 2 to 100 nm. These diminutive droplets, often termed nanoparticles, carry an array of advantages.

Due to their minuscule dimensions, these nanoparticles extend a considerably larger surface area for drug absorption, expediting drug bioavailability. This feature is particularly valuable for drugs encountering absorption challenges primarily driven by their dissolution rate. By maximizing the drug's contact with the absorbent surfaces of the gastrointestinal tract, SMEDDS substantially bolsters drug absorption.

Another critical edge is the adaptability of SMEDDS concerning dosage forms. Unlike conventional emulsions, typically dispensed as solutions, SMEDDS lends itself to encapsulation within an array of solid dosage forms, encompassing hard or soft gelatin capsules or tablets [23]. This formulative flexibility bestows the means to tailor drug delivery solutions that precisely meet the demands of patients and drug compounds.

Excipients in SMEDDS

The selection of excipients in SMEDDS is a pivotal facet that wields substantial influence over the pharmacological suitability of the formulation and the potential toxicity concerns tied to the excipients' constituents. The scope of excipients suitable for SMEDDS formulations is relatively confined, underlining the critical role of excipient selection in the formulation's success.

A multitude of elements influences the self-spreading micro emulsification procedure, encompassing the specific combination of fat and surface-active agent, the density and correlation of surface-active agents, the characteristics of co-surface-active agents, the surface-active agent-to-co-surface-active agent proportion, and the temperature at which emulsification transpires. It is crucial to acknowledge that the successful preparation of self-spreading pharmaceutical transportation systems (SEDDS), a more comprehensive division encompassing SMEDDS, depends on the employment of accurate combinations of pharmaceutical adjuncts. [24].

The choice of oils utilized in SMEDDS formulations emerges as a pivotal decision. Oils assume a pivotal role in enhancing the absorption of lipophilic drugs through the gastrointestinal tract. The molecular composition of triglycerides in these oils promotes the delivery of lipophilic drugs via the intestinal lymphatic system, a critical route for their absorption.

Nonetheless, not all fats align with SMEDDS compositions. While extended and intermediate chain triglyceride (LCT and MCT) oils with varying degrees of saturation have been employed, their capacity to dissolve lipophilic drugs is restricted, discouraging their frequent use as favored lipid additives. In place of these, adapted or broken down vegetable oils have risen in prominence because of their ability to create efficient emulsification systems when combined with an assorted range of surface-active agents.

These systems are deemed safe for oral delivery and also hold the advantage of augmenting drug solubility [25]. The selection of fat resounds as a pivotal factor in the preparation of SMEDDS, resolutely affecting the functionality and solubility of the pharmaceutical.

Moreover, advancements in fat choice have introduced the commencement of groundbreaking semi-synthetic intermediate chain derivates. These derivates can be identified as amphiphilic compounds with surface-active agent attributes. Investigations disclose that intermediate-chain triglycerides (MCT) experience more rapid decomposition compared to long-chain triglycerides (LCT), boasting increased solubility and mobility at the interfaces of lipids and water.

In practical terms, formulations containing long-chain triglycerides (LCT) may require a greater quantity of surfactant to concoct microemulsions compared to those constituted of medium-chain triglycerides (MCT). These innovations in oil selection epitomize the fluidity of SMEDDS formulations, perpetually evolving to elevate drug solubility and absorption [26].

Surfactants in SMEDDS

Surfactants hold an indispensable role in the formation of self-emulsifying systems. Their selection is instrumental, profoundly influencing the solubility of hydrophobic pharmaceutical compounds, intestinal epithelial permeability, tight junction permeability, and the inhibition of p-glycoprotein drug efflux.

Non-ionic surfactants are conventionally favored due to their favorable hydrophilic-lipophilic balance (HLB). Surfactants such as polyoxyethylene 20 oleate and ethoxylated polyglycolyzed glycerides exist in both solid and liquid states and find extensive application, including the popularity of Tween 80.

However, the selection of surfactants for SMEDDS necessitates a prioritization of safety. While synthetic surfactants have seen deployment, there is a growing inclination toward natural emulsifiers due to their enhanced safety profile for human ingestion. This preference is grounded in the generally lower perceived risk associated with natural emulsifiers in contrast to their synthetic counterparts.

Nonetheless, it's vital to recognize that even non-ionic surfactants can bring about transient shifts in the permeability of the intestinal lumen. This potential to modify intestinal permeability necessitates case-by-case evaluation and warrants vigilant scrutiny.

Establishing stable self-microemulsifying drug delivery systems calls for precise calibration of surfactant concentrations, typically spanning from 30% to 60% w/w. Elevated surfactant levels, while beneficial for drug solubility, may pose a risk of gastrointestinal irritation. Thus, the determination of surfactant concentration in the formulation is a matter of crucial

consequence. The delicate equilibrium between surfactant concentration and stability in SMEDDS emerges as a pivotal dimension of formulation development.

The distinctive attributes of surfactants in SMEDDS, encompassing their amphiphilic traits and the establishment of stable oil-water interfaces, make notable contributions to the efficient dissolution of hydrophobic drugs and the crafting of minute oil droplets. The positioning of surfactant molecules at the interface between oil and water holds the key to ensuring stability and efficacy. Yet, this phenomenon also underscores the complexity of surfactant behavior within these systems. In specific scenarios, an escalation in surfactant concentration can yield smaller oil droplets, enhancing stability and solubility. On the other hand, it might precipitate the expulsion of oil droplets into the aqueous phase due to interfacial disruption, potentially impacting the overall performance of the formulation. The intricacies of surfactant behavior underscore the prerequisite for precise formulation control in SMEDDS development [28].

Self-Microemulsifying Drug Delivery Systems (SMEDDS) beckon as a promising frontier in pharmaceutical drug delivery. Their resistance to the fat digestion process, augmented drug loading capacity, and advantages over traditional emulsion-based systems loom as compelling traits. These attributes are poised to transcend vital barriers concerning drug solubility and bioavailability.

Nonetheless, it is essential to fathom that the formulation of SMEDDS assumes the guise of a complex and multi-dimensional undertaking. The discerning selection of excipients, inclusive of the choice of oils and surfactants, emerges as a linchpin for securing optimal drug delivery performance. The intricate harmony between boosting drug solubility and preserving gastrointestinal safety must be vigilantly administered. Additionally, the distinctive properties of SMEDDS, such as the generation of small oil droplets and their implications for drug stability, mandate profound comprehension and precise management during the formulation process.

In closing, the prospects for SMEDDS radiate with optimism, buoyed by their potential to surmount vital challenges pertinent to drug solubility and bioavailability. Yet, their triumphant realization necessitates an in-depth grasp of the intricacies surrounding their formulation and an unwavering commitment to cultivating optimal drug delivery systems that translate to improved patient outcomes.

Co-solvents in Drug Delivery Systems: Elevating Solubility and Formulation Efficiency

Co-solvents, the strategic additives utilized alongside solvents to enhance their solubility capacity, assume a critical role in numerous pharmaceutical delivery systems. They hold particular significance in the field of self-emulsifying drug delivery systems (SEDDS) and self-spreading drug delivery systems (SMEDDS). Co-solvents play an essential part in achieving maximum solubility for inadequately water-dissolvable drugs, and their careful selection exerts a profound impact on the success of these delivery systems. This thorough exploration provides a comprehensive evaluation of the function of co-solvents in SEDDS and SMEDDS, contemplating their potential to elevate drug solubility, the potential benefits of co-solvents like ethanol, propylene glycol (PG), and polyethylene glycol (PEG), and the intricate mechanisms underpinning the self-emulsification process.

The Role of Co-solvents in Self-Emulsifying Drug Delivery Systems (SEDDS)

In the framework of SEDDS, the accomplishment of the necessary drug solubility often requires the use of elevated surfactant concentrations, which can exceed 30% w/w. Nonetheless, co-solvents provide an innovative approach to attain similar solubility goals with a lower total surfactant concentration, preserving the ideal environment for SEDDS formation. By combining a surfactant with a co-surfactant, the interfacial tension at the oil-water boundary can be temporarily reduced, occasionally dropping to a negative threshold. This reduction in interfacial tension leads to the expansion of the boundary, initiating the development of tiny droplets that distribute uniformly. These droplets, in turn, absorb additional amounts of surfactant and surfactant/co-surfactant until an overall equilibrium state is achieved. This entire process occurs due to a phenomenon known as spontaneous emulsification. It's pertinent to note that a substantial cohort of ionic surfactants mandate the presence of a co-surfactant in self-emulsifying systems. Conversely, non-ionic surfactants typically sail smoothly without the adjunct of a co-surfactant [30]. This complex interplay between surfactant and co-surfactant within SEDDS formulation spotlights the critical relevance of co-solvents in achieving the desired solubility of poorly water-soluble drugs. Co-solvents can be judiciously harnessed to optimize the surfactant-to-co-surfactant ratio, thus ensuring the efficiency of spontaneous emulsification while reducing the total surfactant concentration.

Exploring Co-solvents in Self-Spreading Drug Delivery Systems (SMEDDS)

The impact of co-solvents stretches to self-spreading drug delivery systems (SMEDDS), a subgroup of SEDDS designed to function at nanoscale dimensions, ushering in enhanced drug solubility and bioavailability. In the realm of SMEDDS, the selection of surface-active agents and co-surfactants plays a pivotal role in efficiently dissolving drugs. While alcohol-free self-emulsifying microemulsions have been documented, it is crucial to emphasize the potential advantages of co-solvents such as ethanol, propylene glycol (PG), and polyethylene glycol (PEG) in the domain of SMEDDS. These co-solvents possess the unique ability to dissolve substantial quantities of either water-attracting surface-active agents or the pharmaceutical substance within the fat base, essentially assuming the role of co-surfactants. The inclusion of such co-solvents optimizes the composition by improving drug solubility and augments the prospect of refined oral administration for these systems [31]. However, it is crucial to consider the inclination of ethanol and other evaporative co-solvents from typical self-emulsifying compositions to migrate into the coverings of pliable gelatin or firmly sealed gelatin capsules, potentially resulting in the deposition of fat-soluble pharmaceuticals. This phenomenon has been meticulously

documented, casting light on the intricate task of incorporating co-solvents into these systems. Despite the advantages proffered by co-solvents like ethanol or propylene glycol in nurturing drug solubility, there remains a lurking risk of diminishing the ability of alcohol-free formulations to dissolve lipophilic medications. As a corollary, the decision regarding the assimilation of co-solvents into SMEDDS must be an exercise in prudence and a diligent evaluation of the precise requirements of the specific drug and formulation [32].

Mechanisms Underlying Self-Emulsification: A Thermodynamic Perspective

A profound understanding of the mechanisms steering self-emulsification is a linchpin for the efficacious development of SEDDS and SMEDDS. A thermodynamic perspective can unravel the intricate interactions that underpin the self-emulsification process. The calculation of free energy (G) linked with the emulsification process unfolds as a valuable avenue for dissecting the inherent mechanisms. The calculation of free energy, encapsulated in the equation G = N'iri, hinges on critical parameters such as N' (the count of tiny globules with a size of r) and i (boundary energy). This formula highlights the reality that the generation of the boundary between oil and water is not a thermodynamically preferred progression, emerging on its own. In essence, there exists a dearth of robust thermodynamic evidence bolstering the occurrence of spontaneous emulsification in systems categorized as SEDDS. The assessment of self-emulsification procedures has profited from optical microscopy. Groves and Mustafa presented a technique to quantitatively measure the emulsification efficiency of phosphate nonylphenoloxylate (PNE) and phosphated fatty alcohol ethoxylate (PFE) in n-hexane. This was carried out by evaluating the cloudiness of the fat-surface-active agent blend in a stream of water [33]. It is essential to underscore the theoretical proposition set forth by Pouton, forging a link between surfactant emulsification characteristics and its phase inversion behavior. In cases where the temperature of a system constituting a nonionic surfactant-stabilized oil-in-water emulsion escalates, the surfactant can attain its cloud point, triggering subsequent phase inversion. In the phase inversion, the surfactant assumes high fluidity, and the interfacial energy between the oil and water (o/w) declines, effectively curtailing the energy requisite for initiating emulsification. The ease with which emulsion formation materializes could be modulated by the interplay between the degree of specificity demanded for the surfactant mixture to fuel spontaneous emulsification and the scope of phase inversion. Phase inversions prove pivotal for the creation of liquid crystals during the self-emulsification process. Formulations that show success are frequently observed to operate within the phase inversion zone and the region marked by heightened aqueous solubilization [34].

The phase inversion zone of a system composed of 30% w/w Tween and 85/70% w/w medium-chain triglyceride (MCT) oil is noted to possess a transition point at roughly 40°C when diluted in water. This system operates optimally at room temperature up to 60°C, beyond which the emergence of water-in-oil emulsions gains prevalence. The ease with which water infiltrates the oil-water interface can bear influence on the emulsification process, accredited to the formation of liquid crystalline phases and subsequent interface swelling. In systems involving a co-surfactant, there's potential for significant distribution of the constituents across the oil and water phases, an occurrence termed as "diffusion and stranding." This phenomenon entails the solubilization of the oil and its migration into the aqueous phase [35].

Dilution Phases: An Important Mechanism in Self-Emulsification

The notion of dilution phases emerges as a critical component in comprehending self-emulsification. It alludes to the process of decreasing the concentration of a substance within a solution by the addition of a solvent. In the domain of SMEDDS, as the formulation undergoes dilution, the spontaneous curvature of the surfactant layer traverses a sequence of transitions into diverse liquid crystalline phases. These transitions can occasion a shift in the shape of the droplets, transitioning from spherical to other forms, including rod-shaped, hexagonal, and lamellar structures, successively. Significantly, this transformation can be reversed through dilution, ultimately culminating in the reformation of a spherical droplet, as illustrated in Figure 3. The dilution of a lipid formulation in water can lead to the creation of a liquid crystalline phase. This phase transition is attributed to a medley of variables. Notably, Groves and Mustafa observed that emulsification periods accelerated in systems producing liquid crystals through the combination of surfactant and oil mixtures. The authors postulate that the facilitation of water ingress into the droplet, particularly the permeation of the solvent into the liquid crystalline phases established on the droplet's surface, is intrinsically linked to the ease of achieving emulsification. These structures formed during dilution have been identified as contributing factors to both the stability of the diluted microemulsion and the rate at which the medication is released. This phenomenon is attributed to the dissolution of the medication and the digestion of the formulation, both of which are influenced by the existence of a liquid crystalline material layer around the oil droplets [36].

To conclude, the function of co-solvents in self-spreading pharmaceutical transport systems emerges as intricate. Co-solvents present a tactical method to improve pharmaceutical solubility while upholding the effectiveness and constancy of SEDDS and SMEDDS compositions. The choice of co-solvents like ethanol, propylene glycol, and polyethylene glycol (PEG) in SMEDDS brings forth the opportunity to enhance oral delivery and attain improved solubility for inadequately water-dissolvable drugs.

These mechanisms underpinning self-emulsification are intricate, and they hinge on the synergy of various thermodynamic factors. The process isn't inherently favored energetically, and the formation of liquid crystalline phases and dilution phases wield a substantial impact on the emulsification efficiency and steadiness of self-emulsifying method.

To fully leverage the potential of SEDDS, it is imperative to exercise precision and caution when considering the utilization of co-solvents and understanding the mechanisms of self-emulsification. A profound comprehension of these mechanisms is vital for unlocking the full potential of these systems, ultimately translating to enhanced drug solubility and bioavailability and offering groundbreaking solutions to elevate patient outcomes in the realm of pharmaceuticals.



Figure 3. The depiction of the many phases resulting from the introduction of water to a mixture of oil and surfactant.

Optimizing SMEDDS: A Comprehensive Analysis

Self-Microemulsifying Drug Delivery Systems have emerged as a groundbreaking approach to overcoming challenges in pharmaceutical drug delivery. The development and effectiveness of SMEDDS are intricately influenced by a myriad of factors, all of which intertwine to shape the design, performance, and therapeutic potential of these innovative systems. In this comprehensive analysis, we will delve into the nuances of the factors that underpin the optimization of SMEDDS, emphasizing their critical significance in the pharmaceutical landscape.

Nature and Dosage of the Pharmaceutical Compound

The nature and dosage of the pharmaceutical compound represent a pivotal determinant of the suitability of SMEDDS for drug delivery. While SMEDDS offer a versatile platform for enhancing the solubility and bioavailability of a wide range of drugs, not all pharmaceutical compounds are equally amenable to this delivery approach. To fully appreciate the impact of these factors, it's crucial to understand their interplay with the characteristics of the drug molecule itself.

Pharmaceuticals with very large doses may not be the ideal candidates for SMEDDS unless they exhibit exceptional solubility in at least one of the components of SMEDDS, preferably within the lipophilic phase. In such cases, the sheer quantity of the drug could pose challenges in terms of formulation volume and stability. The Log P value, a fundamental parameter denoting a compound's solubility in both water and lipids, often serves as an indicator of the difficulties faced in administering drugs via SMEDDS.

For pharmaceuticals with Log P values hovering around 2, indicating limited solubility in both aqueous and lipid environments, incorporating them into SMEDDS can be a challenging endeavor. The solubility of the drug in the oil phase plays a pivotal role in maintaining it in a solubilized state within the SMEDDS. However, as SMEDDS undergoes dilution in the gastrointestinal tract, the capacity of the surfactant or co-surfactant to hold the drug may diminish, raising the risk of drug precipitation.

A well-founded approach to predict and manage drug precipitation is through equilibrium solubility measurements. Yet, it's imperative to recognize that the actual crystallization process may proceed slowly due to the solubilizing and colloidal stabilizing environment of the gastrointestinal tract. Pouton's research sheds light on the extended timeframe for equilibrium solubility and precipitation of drugs within SMEDDS, suggesting that achieving equilibrium may take up to five days. This prolonged supersaturation enhances drug absorption by increasing thermodynamic activity, thereby diminishing the chances of drug precipitation in the gastrointestinal tract before absorption. However, a substantial need exists for the development of more robust predictive methods to accurately ascertain the fate of drugs within the gastrointestinal tract following SMEDDS administration.

The Polarity of the Lipophilic Phase

The polarity of the lipophilic phase in SMEDDS is a critical factor that profoundly influences drug release from microemulsions. It encompasses an intricate interplay of variables, including the hydrophilic-lipophilic balance (HLB), the length and unsaturation of fatty acid chains, molecular weight, and the use of micronized fatty acids. Understanding how these elements impact the polarity of the lipid phase is essential to exploit their potential in enhancing drug solubility and bioavailability.

Micronized fatty acids play a pivotal role in inhibiting crystallization, facilitating the generation and maintenance of a supersaturated state over an extended period. The strategic use of hydroxypropyl methylcellulose (HPMC) as a precipitation inhibitor in conventional SMEDDS has led to the development of super saturable SMEDDS (S-SMEDDS) for the administration of drugs like paclitaxel. This innovative approach showcases the manipulation of the polarity of the lipophilic phase to optimize drug delivery.

In S-SMEDDS formulations, dilution triggers the formation of a microemulsion, followed by the gradual crystallization of the drug over time. It is noteworthy that the presence of HPMC in the formulation significantly contributes to the prolonged maintenance of a supersaturated state. Conversely, the absence of HPMC leads to rapid precipitation of the drug, yielding a diluted solution. Pharmacokinetic analysis reveals a substantial increase in maximum concentration

(Cmax) and oral bioavailability (F) for the S-SMEDDS formulation compared to other administration methods, underscoring the clinical significance of polarity manipulation in SMEDDS formulations.
The implication here is that by understanding and modifying the polarity of the lipophilic phase, we can enhance the therapeutic efficacy and bioavailability of poorly soluble drugs. This represents an exciting frontier in pharmaceutical research, with the potential to revolutionize the treatment of various medical conditions.

Biopharmaceutical Aspects

Biopharmaceutical factors are pivotal in shaping the effectiveness of SMEDDS, particularly for drugs with low water solubility. The influence of dietary fats on drug bioavailability provides a solid foundation for the development of lipid-based self-emulsifying formulations. The precise mechanisms through which dietary lipids enhance drug bioavailability are complex and multifaceted, but they provide critical insights into the interplay between food, medication, and the gastrointestinal environment.
The presence of lipids in the digestive tract may extend the gastric transit time, affording more time for drug substances to disintegrate and be absorbed at the absorption site. This alteration in gastrointestinal dynamics can have a profound impact on the efficiency of medication delivery, making it a crucial biopharmaceutical consideration.
Furthermore, the presence of dietary fats in the gastrointestinal tract stimulates the synthesis of bile salts (BS), phospholipids (PL), and cholesterol (CH), which collectively lead to the formation of mixed micelles. These mixed micelles significantly enhance the solubilization capacity of the gastrointestinal system. Exogenous lipids, whether directly or after undergoing digestion, amplify the structural changes in the micellar environment, increasing its solubilization capability. These structural transformations are pivotal in enhancing drug dissolution and bioavailability.
Lipids can also promote drug absorption by facilitating their movement through the lymphatic system and potentially reducing first-pass metabolism. Highly hydrophilic pharmaceutical compounds may bypass the lymphatic absorption pathway, instead entering the portal circulation. In such cases, the emulsion formed in SMEDDS serves as a vital factor in increasing dissolution and absorption.
Furthermore, specific lipids and surfactants have been identified to inhibit the activity of the p-glycoprotein efflux pump in the intestines. This inhibition can modify the biochemical barrier function of the gastrointestinal tract, enhancing drug absorption.
Moreover, changes in the physical barrier function of the gastrointestinal system are observed with SMEDDS. The synergy between different lipid species, lipid degradation byproducts, and surfactants enhances permeability, further increasing the potential for drug absorption. This is particularly significant for weakly water-soluble, lipophilic drugs, where passive permeability is not a substantial barrier. Nevertheless, these intricate mechanisms necessitate further exploration to provide a comprehensive understanding of their impact on drug bioavailability within SMEDDS.

Susceptibility to Digestion

One aspect that is often overlooked in the context of SMEDDS is the susceptibility of a substance to digestion. The presence of lipids in the gastrointestinal tract, both endogenous and exogenous, significantly enhances the absorption of medications. The beneficial effect of food on drug bioavailability offers a foundational rationale for developing lipid-based self-emulsifying formulations, even though the composition, quantity, and nature of dietary lipids can substantially differ from the oil phases in pharmaceutical formulations.
The mechanisms through which lipids in the gastrointestinal tract promote drug solubilization and dissolution are complex and multifaceted. They involve a synergy of endogenous and exogenous lipids, the formation of mixed micelles, and changes in the physical barrier function of the gastrointestinal system.
These mechanisms make SMEDDS an effective platform for improving drug bioavailability, particularly for poorly soluble drugs. However, continued research is essential to fully elucidate the intricate interactions between dietary lipids, pharmaceutical formulations, and their impact on drug bioavailability. This knowledge will empower the development of optimized SMEDDS that harness the potential of these mechanisms.

Categorization of Lipid-Based Formulations

Pouton's categorization of lipid-based formulations into three distinct classes has been instrumental in the development of SMEDDS. This categorization streamlines the selection of excipients and formulation strategies based on the specific needs of the drug being delivered.
Category I encompasses basic drug solutions in triglycerides and mixed glycerides. These formulations are straightforward and user-friendly, making them suitable starting points for lipid-based drug delivery. They are often chosen when simplicity and convenience are paramount.
Category II formulations are characterized by the inclusion of a lipophilic surfactant with an HLB of approximately 12. These formulations strike a balance between simplicity and enhanced drug solubilization and self-emulsifying properties. They are versatile and serve as a bridge between basic lipid solutions and more complex formulations.
Category III formulations, which are instrumental in creating SMEDDS, utilize hydrophilic surfactants with an HLB of around -12, along with co-solvents. These excipients facilitate self-emulsification in the gastrointestinal tract. Category III can be further divided into two subtypes: Type IIIA and Type IIIB.

Notably, Type IIIB formulations contain a higher proportion of hydrophilic components relative to lipophilic components. These formulations tend to enhance self-emulsification and reduce lipid droplet size, which, in turn, results in better drug

solubilization. However, they also carry an increased risk of drug precipitation, as the separation of hydrophilic and lipophilic components during dispersion can lead to decreased drug solubility.

The use of ternary phase diagrams has proven to be invaluable in determining excipient combinations for SEDDS/SMEDDS formulations. These diagrams provide a visual representation of the compatibility of oil, surfactant, and co-surfactant. In cases where formulations contain more than three excipients, a pair of excipients, such as the surfactant and co-surfactant, may be treated as a single component with a fixed ratio between them.

Evaluating these formulations in biorelevant, simulated physiological fluids is imperative to determine their self-emulsification properties. The analysis of dispersion and lipid droplet size classification can be conducted using various visualization and light scattering techniques. These techniques facilitate the classification of the formulation as either a Self-Emulsifying Drug Delivery System (SEDDS) or a Self-Microemulsifying Drug Delivery System (SMEDDS).

In conclusion, the optimization of Self-Microemulsifying Drug Delivery Systems (SMEDDS) is a multifaceted endeavor, influenced by a complex interplay of factors. The nature and dosage of the pharmaceutical compound, the polarity of the lipophilic phase, biopharmaceutical aspects, susceptibility to digestion, and the categorization of lipid-based formulations all contribute to the design, performance, and therapeutic potential of SMEDDS.

To unlock the full potential of SMEDDS, a profound understanding of these factors is essential. Ongoing research and exploration of the intricate interactions between these elements will undoubtedly pave the way for the development of optimized SMEDDS formulations that enhance drug solubility, bioavailability, and, ultimately, patient outcomes in the realm of pharmaceuticals.



Figure 4. Microscopic characterization of SEDDS.

Emulsion Droplet Size and Its Influence on Drug Absorption: A Comprehensive Analysis

The impact of emulsion droplet size on drug absorption is a subject of substantial interest in the pharmaceutical domain. It is well-established that reducing the size of lipid droplets can potentially enhance drug absorption. However, the relationship between droplet size and drug bioavailability is far from straightforward, as illustrated by the intriguing findings of Khoo et al. in their study on the antimalarial drug halofantrine. This study revealed that halofantrine's bioavailability remained consistent whether administered in a Microemulsion-based Self-Emulsifying Drug Delivery System (MC-SEDDS) with a mean lipid droplet size of 119 nm or a Microemulsion-based Self-Microemulsifying Drug Delivery System (MC-SMEDDS) with a mean lipid droplet size of 52 nm. This counterintuitive discovery challenges the conventional wisdom that smaller droplets invariably lead to improved drug absorption.

Furthermore, human studies comparing the self-microemulsifying Neoral® formulation of cyclosporine with the Sandimmune formulation add complexity to the relationship between droplet size and drug absorption. While the Sandimmune formulation results in a crude emulsion in the gastrointestinal tract, the Neoral formulation offers superior performance in terms of the rate, extent, homogeneity, and linearity of cyclosporine exposure concerning dosage. Notably, the Neoral formulation exhibits a reduced susceptibility to the influence of meals on its absorption compared to the Sandimmune formulation.

Nonetheless, it is essential to recognize that these studies employed distinct lipid and surfactant systems, and these variations significantly influence the absorption of medications, potentially yielding conflicting experimental outcomes. This diversity in formulations underscores the complexity of the relationship between lipid droplet size and drug absorption. Additionally, these studies suggest that the influence of lipid droplet size on formulation performance may be negligible until it interferes with the normal lipid digestion process, causing the formation of a fine emulsion following lipid ingestion.

In-Vivo Investigations Utilizing Self-Emulsifying Drug Delivery Systems (SEDDS) and Self-Microemulsifying Drug Delivery Systems (SMEDDS)

To comprehensively explore the impact of droplet size on drug absorption, we must consider in-vivo investigations that employ Self-Emulsifying Drug Delivery Systems (SEDDS) and Self-Microemulsifying Drug Delivery Systems (SMEDDS). These innovative formulations have exhibited remarkable enhancements in drug bioavailability across a diverse spectrum of drugs, surpassing the performance of conventional solid dosage forms, water-miscible glycol solutions (such as PEG and propylene glycol), and basic oil solutions. For example, self-emulsifying formulations have significantly improved the bioavailability of drugs like simvastatin, which demonstrated a 1.5-fold increase, and L-365,260, which exhibited an approximately seven-fold increase compared to conventional solid dosage forms of cholecystokinin antagonists.

This compelling evidence emphasizes that the choice of excipients and the physicochemical properties of the drug ingredient play pivotal roles in determining a formulation's capacity to enhance drug bioavailability. However, it is essential to critically assess the limitations and challenges inherent in these investigations. The outcomes are prone to be influenced by several factors, including variations in the selection of drug compounds and the choice of excipients in different formulations. Additionally, these studies frequently rely on the use of animal models, which may not entirely replicate the complexities of human physiology and drug absorption. To ensure the applicability of these findings to human pharmaceuticals, one must consider the translational implications.

The Impact of Dispersion on Bioavailability

The intricate relationship between emulsion droplet size and drug bioavailability gains further complexity when we consider the effect of dispersion. In general, self-emulsifying formulations have demonstrated only modest improvements in drug bioavailability compared to conventional oil-based solutions. Nevertheless, it is imperative to appreciate the subtleties within this observation.

The experiments have been carried out across different species, employing a variety of formulations and doses of lipids and surfactants, which has resulted in discrepancies in results even within specific studies. Moreover, the participants in these studies were generally in good health, possessing fully matured gastrointestinal lipid handling pathways. Under such conditions, the utilization of self-emulsifying formulations may not significantly enhance drug absorption.

However, it is essential to underscore that these findings do not negate the potential advantages of self-emulsifying formulations. Instead, they underscore the contextual nature of these advantages. The observations indicate that the utilization of self-emulsifying formulations becomes particularly crucial when the normal physiological processes involved in fat digestion and dispersion are disrupted, leading to the formation of a fine emulsion post-lipid ingestion.

Conclusion

In summary, the critical analysis presented here underscores the intricate and context-dependent nature of the relationship between emulsion droplet size and drug absorption. Although smaller droplets are often associated with improved absorption, exceptions and subtleties exist, necessitating a nuanced comprehension of the interplay between droplet size, formulation, and physiological conditions.

Self-Microemulsifying Drug Delivery Systems (SMEDDS) exhibit significant potential in formulating drugs with limited solubility in aqueous environments. They have demonstrated the capability to substantially enhance the oral bioavailability of hydrophobic drugs, rendering oral administration feasible for compounds that would otherwise pose formulation challenges. Solidified SMEDDS (S-SMEDDS) offer several compelling advantages, including reduced manufacturing costs, streamlined industrial production processes, enhanced stability, and improved patient adherence.

It is paramount to acknowledge the limitations of these findings. Most in-vivo investigations have relied on animal models, necessitating cautious consideration of the translational implications to human pharmaceuticals. The contextual nature of drug absorption enhancements through self-emulsifying formulations underscores the importance of considering the specific drug compounds, excipients, and physiological conditions under which these formulations are administered.

To unlock the full potential of self-emulsifying drug delivery systems, further comprehensive research is warranted, especially with regard to human bioavailability and the correlation between in vitro and in vivo data. Addressing these knowledge gaps will empower the pharmaceutical industry to harness the full potential of self-emulsifying drug delivery systems and to further refine the design and utilization of these formulations in a manner that improves patient outcomes and the therapeutic landscape.

References

1. Akihiko, I., Masayasu, S., 1996. Development of oral dosage form for elderly patients: use of agar as base of rapidly disintegrating tablets, *Chem. Pharm Bull,* 45, 2132-2136.
2. Amaral, M.H., Lobo, J.M., Ferreira, D.C., 2001. Effect of hydroxyl propyl methyl cellulose and hydrogenated castor oil on naproxen release tablets. *AAPS PharmSciTec.*2 (2), 1-8.
3. Cao, Q.R., Choi, Y.W., Cui, J.H., Lee, B.J., 2005. Formulation release characteristics and bioavailability of novel monolithic hydroxylpropyl methylcellulose matrix tablets containing acetaminophen. *Journal of Controlled Release*, 108, 351-361.
4. Chandrashekar, N.S., Kulkarni, P.K., Parimala, P., 2006. Formulation and evaluation of fast dissolving tablets of rofecoxib. *International Journal of Pharmaceutical Excipient,* 14-17.
5. Chaudhari P.D., Chaudhari, S.P., Kolhe, S.R., Dave, K.V., More, D.M., 2005. Formulation and evaluation of fast dissolving tablets of femotidine. Indian Drugs, 42 (10), 641-648.
6. Chien, Y.W., 1992. *Novel Drug Delivery System.* 2nd ed. New York: Marcel Decker.221.
7. Choi, H.G., Yong, C., 2000. Development of terfenadine – pseudoephedrine double-layer tablet dissolution equivalent to core tablet. *Drug Development and Industrial Pharmacy*, 26 (6), 605-611.
8. Defang, O., Hong, G., Hui, L., Weisan, P., 2005. In-vitro and in-vivo evaluation of two extended release preparations of combination metformin and glipizide. *Drug Development and Industrial Pharmacy,* 31, 677-685.
9. Fausett, H., Charles, G.J., Alekha, K.D., 2002. Evaluation of quick disintegrating calcium carbonate tablets. *AAPS PharmSciTech*, 1 (3), 20.

10. Ferror, C., Munoz, N., Velasco, M.V., 1997. Disintegrating efficiency of crosscarmallose sodium in a direct compression formulation. *International Journal of Pharmaceutics*, 147, 11-21.
11. Gedela, V.M., Nambulla, R.M., Kasina, H.S., Battu, J.R., 2002. In-vitro evaluation of modified gum karaya as a carrier for improving the oral bioavailability of a poorly water-soluble drug. *AAPS PharmSciTech*, 3 (2), 1-9.
12. Ishikawa, T., Watanabe, Y., Takayama, K., 2000. Effect of hydroxylpropyl methylcellulose (HPMC) on the release profiles and bioavailability of a poorly water-soluble drug from tablets prepared using macrogol and HPMC. *International Journal of Pharmaceutics*, 202, 173-178.
13. Jain, G., Goswami, J., 2005. Studies on formulation and evaluation of new superdisintegrants for dispersible tablets. *International Journal of Pharmaceutical excipient,* 37-43.
14. Karande, A.D., Dhoke, S.V., Yeole, P.G., 2005. Formulation and evaluation of bilayer tablet with antihypertensive drugs having different release pattern. *Indian Drugs*, 43 (1), 44-50.
15. Kiortsis, S., Kachrimanis, K., Broussali, T., Malamataris, S., 2005. Drug release from tableted wet granulations comprising cellulosic (HPMC or HPC) and hydrophobic component. *European Journal of Pharmaceutics and Biopharmaceutics*, 59, 73-83.
16. Lopes, C.M., Costa, P., Pinto, J.F., 2006. Directly compressed tablets containing ibuprofen: preparation and evaluation of sustained release. *Drug Development and Industrial Pharmacy*, 32, 98-106.
17. Maggi, L., Machiste, E.O., Torre, M.L., Conte, U., 1998. Formulation of biphasic release tablets containing slightly soluble drugs. *European Journal of Pharmaceutics and Biopharmaceutics*, 48, 37-42.
18. Narendra, C., Srinath, M.S., Babu, G., 2006. Optimization of bi-layer floating tablet containing metoprolol tartarate as a model drug for gastric retention. *AAPS PharmSciTech*, 7 (2), E1-E7.
19. Notari, R.E., 2005. *Biopharmaceutics and Clinical Pharmacokinetics*. 4th ed. New York, Marcel Decker: 140-141.
20. Reddy, K.R., Mutalik, S., Reddy, S., 2003. Once daily sustained release matrix tablets of nicorandil: formulation and In-vitro evaluation. *AAPS PharmSciTech*, 4 (4), 1-9.
21. Savaser, A., Ozkan, Y., Isimer, A., 2005. Preparation and In-vitro evaluation of sustained release tablet formulation of Diclofenac sodium. *IL Farmaco*, 60, 171-177.
22. Shenoy, V., Agarwal, S., Pandey, S., 2003. Optimizing fast dissolving dosage form of Diclofenac sodium by rapidly disintegrating agents. *International Journal of Pharmaceutical Science*, 197-201.
23. Sunada, H.Y., Yonezawa, Y., Danjo, K., 1999. Evaluation of rapidly disintegrating tablets prepared by a direct compression method. *Drug Development and Industrial Pharmacy*, 25 (5), 571-581.
24. Swarbrick, J., Boylan, J.C., 2002. Superdisintegrants: Characterization and function. *In:* L.L. Augsburger. 2nd ed. *Encyclopedia of Pharmaceutical Technology.* New York, Marcel Dekker; 2623-2623.
25. Tortora, G.J., Grabowski, S.R., 1996. *Principles of Anatomy and Physiology.*8th ed. Place of publication: Harpercollins College Publisher, 774-775.
26. Venkatramana, M.R., Kevin, E., Yihong, Q., 2003. Design of pH-independent controlled release matrix tablets for acidic drugs. *International Journal of Pharmaceutics*, 252, 81-86.
27. Vueba, M.L., Carvalho, L.A., Leiga, F., 2005. Role of cellulose ether polymers on ibuprofen release tablets. *Drug Development and Industrial Pharmacy*, 31, 653-665.
28. Zhao, N., Augsburger, L.L., 2005. Functionality comparison of 3 classes of superdisintegrants in promoting aspirin tablet disintegration and dissolution. *AAPS PharmSciTech*, 6 (4), E634-E640.
29. Zhao, N., Augsburger, L.L., 2005. The influence of swelling capacity of superdisintegrants in different pH media on the dissolution of hydrochlorothiazide from directly compressed tablet. *AAPS PharmSciTech*, 6 (1), E120-E126.
30. Saikrishna, Kalakuntala *et al*., 2014. Formulation and Evaluation of Floating Bilayer Tablets of Atenolol and Lovastatin by using Natural Polymers. Int J Pharm Bio Sci., 4(4): 1 – 19.
31. Ryakala, Harika *et al.*, 2015. Formulation and In Vitro Evaluation of Bilayer Tablets of Nebivolol Hydrochloride and Nateglinide for the Treatment of Diabetes and Hypertension. Journal of Drug Delivery, Article ID 827859, 1-15.
32. Rubric, E.M., Schwartz, J.D., 2001, Oral solid dosage form in: Remington- the science and practice of pharmacy' 20th edition, Lippincott Williams and Wilkins, 1, 859 – 871.
33. The Merck index, An encyclopedia of chemicals, drugs and biologicals, 14th edition, published by Merck Research Labs.
34. Tousey, M.D., Pharmaceutical technology, tabletting and granulation (Available from: http://www.pharmtech.com).
35. Vinod P. Shah, A.S. Hussain, Dissolution profile comparison using similarity factor f_2, *Office of Pharmaceutical Sciences,* CDER, FDA, Rockvile MD.
36. Vladi O. Consiglieni, Tiago Martinello, Telma Marrie Kaneko, Maria Elena Santos, 2006, Optimization of poorly compactable drug tablets manufactured by direct compression using the mixture experimental design, *Int. J. Pharm.*, 322, 87 – 95.
37. Peter, Kleinebade, 2003, Roll compaction/ dry granulation: Pharmaceutical Application, *European J. Pharm. Biopharm.*, 19, 373 - 379.
38. Physicians Desk Reference., 2004, Published by medical economics company Inc., 58th edition, 317,1621-1625
39. Randall, C.S., 1995, Physical characterization of pharmaceutical solids, Marcel Dekker Inc New York, 180 – 182.
40. Raymond C. Rowe, H. Kibbe,2003, Handbook of Pharmaceutical Excipients, 4th edition, Publisher- Science and Practice, Royal Pharmaceutical Society of Great Britain, London UK.

41. Akula S, Gurram AK, and DevireddySR. Review on:Self-Micro-Emulsifying Drug Delivery System: An Attractive Stratergy for Enhance Therapeutic Profile. International Scholarly Research Notices, 2014; 11(8): 1-4.
42. Deshmukh AS. Review on:Recent Advances in Self Emulsifying Drug Delivery System. International Journal of Pharmaceutical Science and Nanotechnology (IJPSN), 2015; 8 (1): 3-4.\
43. Deshmukh AS, Mahajan VR. Review on: Advanced Delivery of Poorly Water Soluble Drug By Lipid Based Formulation as (SMEDDS). Asian Journal of Research in Biological and Pharmaceutical Science,2015; 3 (1): 15-18.
44. Deshmukh AS, Mahajan VR. Review on: Advanced Delivery of Poorly Water Soluble Drug Atrovastain By Lipid Based Formulation as (SMEDDS). Asian Journal of Pharmaceutical Research and Development,2015; 3 (2): 22-29.
45. Dokania S, Joshi AK. Review on:Self-Micro-Emulsifying Drug Delivery System (SMEDDS) – Challenges and Road Ahead. Drug Delivery Informa Healthcare,2014; 22(6): 677.
46. Gadhe LT, Kapadi SV, Bachkar B, Gandhi M Review on: Recent Patent Review on Self-Micro-Emulsifying Drug Delivery System.World Journal of Pharmaceutical Research, 2015; 4 (3): 970.
47. Gahlawat N, Verma R, Kaushik D. Review on: Recent Development in Self-Micro-Emulsifying Drug Delivery System: An Overview. Asian Journal of Pharmaceutics, 2019; 13(1):59- 60.
48. Gautam P, Shastri D. Review on: Self –Micro Emulsifiying Drug Delivery System to enhance the solubility of the hydrophobic drugs. Current Trends InBiomedical Engineering and Biosciences (JP Juniprer), 2018; 13(4): 60.
49. Gupta RN, Gupta R, Rathore GS. Review on: Enhancement of Oral Bioavailability of Lipophilic Drug Delivery System (SMEDDS). International Journal of Drug Development and Research, 2009: 1(1):13.
50. Jaiswal JJ, Solanki AJ, Yadav SK. Review on: A Review on Solid Self Microemulsifying Drug Delivery System: Formulation Strategies to Improve the Bioavailability of Poorly Soluble Drug. Journal of Pharmaceutical Science and Bioscientific Research (JPSBR), 2016; 6(3):241.
51. Kalamkar P, Pawar K, Baddi H, Thawkar B, Yevale R, Dr. Kale M " Self- Micro-Emulsifying Drug Delivery System (SMEDDS). International Journal of Pharmacy and Pharmaceutical Research (IJPPR).2016; 6(3): 370
52. KhedekarK, Mittal S. Review on: Self -Micro-Emulsifying Drug Delivery System. International Journal Pharmaceutical Science and Research.2013; 4 (12):4497- 4498.
53. Maurya SD, Arya RK, Rajpal G, Dhakar RC. Review on: Self-Micro-Emulsifying Drug Delivery Systems (SMEDDS): A Review on Physico-Chemical and Biopharmaceutical Aspect. Journal of Drug Delivery and Therapeutics, 2017; 7(3):59- 60
54. Pattewar SV, Kasture S, Pande V, Sharma S. Review on: Self-Micro-Emulsifying Drug Delivery System: A Lipid Based Drug Delivery System. International Journal of Pharmaceutical Sciences and Research, 2016; 7(2): 443-448.
55. Pawar SD, Gujrathi NA, Rane BR, Pawar SP. Review on: Self-Micro-Emulsifying Drug Delivery System (SMEDDS): A Promising Drug Delivery System for Enhancement of Bioavailability. Indian Journal of Drug, 2016; 4(3):6-7.
56. Potphode VR, Deshmukh AS, Mahajan VR. Review on; Self-Micro-Emulsifying Drug Delivery System: Approach for Enhancement of Bioavaibility of Poorly Water Soluble Drugs. Asian J. Pharma Tech, 2016; 6(3): 63-65.
57. P. Reddy UM, P. Babu R, P. Rao M, Edukoudalu V, Malikharjunarao KR. A Review on: Self-Microemulsifying Drug Delivery System. International Journal of Research in Pharmaceutical and Nano Sciences, 2013; 2(3):319.
58. P. Tripura S, P. Mounika. Formulation and Evaluation of SMEDDS Containing Febuxostat By Employing Arachis Oil and Labrasol As Oil and Surfactant System. World Journal of Pharmaceutical Research, 2018; 7(11): 543- 545.
59. Reddy S, Katyayani T, Navatha, A, Ramya G. Review on Self- Micro-Emulsifying Drug Delivery System. International Journal of Research in Pharmaceutical Sciences, (2011); 2(3):383- 386.
60. Sharma VK, Koka A, Yadar J, Sharma AK., Keservani RK. Review on: Self-Micro-Emulsifying Drug Delivery System: A Strategy to Improve Oral Bioavailability. Ars Pharmaceutical, 2016; 57(3):102, 99.